Evidence map›Paper›PMID 38569124›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Validating Risk Prediction Models for Multiple Primaries and Competing Cancer Outcomes in Families With Li-Fraumeni Syndrome Using Clinically Ascertained Data.

Nam H Nguyen, Elissa B Dodd-Eaton, Jessica L Corredor, Jacynda Woodman-Ross, Sierra Green, Angelica M Gutierrez, Banu K Arun, Wenyi Wang

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nam H NguyenThe University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computation Biology, Houston, TX.
Elissa B Dodd-EatonThe University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computation Biology, Houston, TX.
Jessica L CorredorThe University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Genetics, Houston, TX.
Jacynda Woodman-RossThe University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Genetics, Houston, TX.
Sierra GreenThe University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Genetics, Houston, TX.
Angelica M GutierrezThe University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX.ORCID 0000-0002-8582-8186
Banu K ArunThe University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Genetics, Houston, TX.ORCID 0000-0002-5475-8509
Wenyi WangThe University of Texas MD Anderson Cancer Center, Department of Bioinformatics and Computation Biology, Houston, TX.ORCID 0000-0003-0617-9438
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53R01CA239342 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2019 to 2022
$1.5M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA239342
6 · The paper itself

Abstract

purposeThere exists a barrier between developing and disseminating risk prediction models in clinical settings. We hypothesize that this barrier may be lifted by demonstrating the utility of these models using incomplete data that are collected in real clinical sessions, as compared with the commonly used research cohorts that are meticulously collected. MATERIALS AND

methodsGenetic counselors (GCs) collect family history when patients (ie, probands) come to MD Anderson Cancer Center for risk assessment of Li-Fraumeni syndrome, a genetic disorder characterized by deleterious germline mutations in the

resultsFor prediction of deleterious

conclusionWe describe a study that fills in the critical gap in knowledge for the utility of risk prediction models. Using a CCB cohort, our previously validated models have demonstrated good performance and outperformed the standard clinical criteria. Our study suggests that better risk counseling may be achieved by GCs using these already-developed mathematical models.

Indexed as

Li-Fraumeni SyndromeAdultFemaleGenes, p53Genetic CounselingGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedNeoplasms, Multiple PrimaryRisk AssessmentTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID38569124
PMCPMC11191065
OpenAlexW4393901428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.